AstraZeneca's rosuvastatin ['Crestor'] significantly reduces levels of LDL-cholesterol in patients with hypercholesterolaemia, according to new data presented recently at the 50th Annual Scientific Session of the American College of Cardiology [Orlando, US; March 2001]. Rosuvastatin reduced LDL-cholesterol levels by 40-58%; this improvement was significant, compared with other HMG CoA reductase inhibitors [statins], atorvastatin, simvastatin and pravastatin. Furthermore, rosuvastatin increased levels of HDL-cholesterol by up to 13%, and up to 87% of rosuvastatin recipients met recommended target cholesterol levels.